Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib/erlotinib-induced …
H Toba, S Sakiyama, H Takizawa… - The Journal of Medical …, 2016 - jstage.jst.go.jp
Background: Gefitinib and/or erlotinib-induced hepatotoxicity sometimes lead to treatment
failure in EGFR mutation-positive patients with non-small cell lung cancer (NSCLC), even …
failure in EGFR mutation-positive patients with non-small cell lung cancer (NSCLC), even …
Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer
Y Zenke, S Umemura, E Sugiyama, K Kirita… - Lung Cancer, 2016 - Elsevier
Hepatotoxicity is a major cause of the withdrawal of epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) when treating EGFR mutation-positive non-small cell …
tyrosine kinase inhibitors (EGFR-TKIs) when treating EGFR mutation-positive non-small cell …
Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity
K Kunimasa, H Yoshioka, M Iwasaku, A Nishiyama… - Internal …, 2012 - jstage.jst.go.jp
Gefitinib and erlotinib are first-generation small molecular inhibitors of EGFR tyrosine kinase
activity. To the best of our knowledge, to date, two reports have stated that patients with …
activity. To the best of our knowledge, to date, two reports have stated that patients with …
Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity
K Yonesaka, T Suzumura, H Tsukuda… - Anticancer …, 2014 - ar.iiarjournals.org
Aim: To evaluate the tolerability and efficacy of erlotinib treatment in advanced non-small
cell lung cancer (NSCLC) patients who had previously experienced severe hepatotoxicity …
cell lung cancer (NSCLC) patients who had previously experienced severe hepatotoxicity …
Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations
H Kitade, T Yamada, S Igarashi, K Hokkoku… - Gan to Kagaku ryoho …, 2013 - europepmc.org
We report a case of a female in her 80s who was diagnosed with recurrent lung
adenocarcinoma after primary surgery. She was treated with a systemic chemotherapy …
adenocarcinoma after primary surgery. She was treated with a systemic chemotherapy …
Treatment of Non‐Small‐Cell Lung Cancer with Erlotinib following Gefitinib‐Induced Hepatotoxicity: Review of 8 Clinical Cases
Y Yano, Y Namba, M Mori, Y Nakazawa… - Lung Cancer …, 2012 - Wiley Online Library
Objective. Gefitinib often induces liver damage. A few reports have described that the
subsequent administration of erlotinib was associated with less hepatotoxicity, but the safety …
subsequent administration of erlotinib was associated with less hepatotoxicity, but the safety …
Successful treatment of non-small cell lung cancer with afatinib after gefitinib-induced hepatotoxicity
A Imai, T Hachiya, Y Ikuyama, K Sonehara… - Gan to Kagaku ryoho …, 2016 - europepmc.org
A 71-year-old man was referred to our hospital for treatment of non-small-cell lung cancer
(adenocarcinoma of the lungs, with multiple bone metastases, cT1bN0M1b, harboring an …
(adenocarcinoma of the lungs, with multiple bone metastases, cT1bN0M1b, harboring an …
Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy
Y Sugiura, E Nemoto, O Kawai, Y Ohkubo… - Lung Cancer: Targets …, 2013 - Taylor & Francis
Background Gefitinib is known as one of the agents for treating patients with both advanced
lung cancer and an epidermal growth-factor receptor mutation. In the epidermal growth …
lung cancer and an epidermal growth-factor receptor mutation. In the epidermal growth …
Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity
GY Ku, A Chopra, G de Lima Lopes Jr - Lung Cancer, 2010 - Elsevier
INTRODUCTION: Hepatotoxicity secondary to gefitinib, an oral tyrosine kinase inhibitor (TKI)
against the epidermal growth factor receptor (EGFR), is under-appreciated, even though it …
against the epidermal growth factor receptor (EGFR), is under-appreciated, even though it …
Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation
O Yamaguchi, K Kaira, A Mouri, A Shiono… - Cancer chemotherapy …, 2019 - Springer
Background Re-challenge of erlotinib after gefitinib failure is reported to yield some benefit
in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor …
in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor …